UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.
A combination of remdesivir, a drug currently approved in the United States for treating COVID-19 patients, and repurposed drugs for hepatitis C virus (HCV) was 10 times more effective at inhibiting SARS-CoV-2, the virus that causes COVID-19.
A Michigan Medicine team’s online guidelines have been viewed more than 30,000 times by providers in 150 countries since the beginning of the pandemic–and their deployment of an effective COVID-19 therapy has been a model for health systems and hospitals statewide.
Using advanced computational simulations, researchers at the University of Chicago have revealed just how remdesivir works at the molecular level, and also found that two drugs that work in a similar manner, ribavirin and favilavir, do not bind as effectively to the virus.
Researchers from the National University of Singapore have utilised a ground-breaking AI platform to find an optimal combination of available therapies against COVID-19. The research team identified the drug combination from over 530,000 possibilities within two weeks, cutting down the number of tests typically needed by hundreds of thousands.
COVID-19 and Monoclonal Antibodies – Emergency Use Authorization for Bamlanivimab The FDA’s Emergency Use Authorization to treat high risk COVID-19 patients with the monoclonal antibody bamlanivimab will offer limited availability in Texas, where only 6,000 government doses are expected next…
In a review of evidence from the most reliable data from randomized trials to find likely small-to-moderate effects of remdesivir, researchers say that totality of evidence compiled before the WHO trial results justifies compassionate use of remdesivir for severely ill patients. A smaller trial in China showed significantly decreased mean recovery time but no suggestion of a mortality benefit. ACTT-1 found the same mean recovery time and a suggestion of a mortality benefit that did not achieve statistical significance.
J. Randall Curtis, MD, MPH is Chair in Pulmonary and Critical Care Medicine, Department of Medicine | UW Medicine; past-president of the American Thoracic Society He says with regard to Remdesivir: “I think the data suggests that there is probably some benefit in terms…
Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA. The results of the new study, published today by the Nature Research journal Scientific Reports, support the use of the FDA-approved hepatitis C drug EPCLUSA—Sofosbuvir/Velpatasvir—in combination with other drugs in COVID-19 clinical trials.
On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.
A new analysis by University of Chicago Medicine faculty, staff and collaborators around the world found remdesivir appears to be equally beneficial to patients regardless of race, supporting the need for early intervention and aggressive care for all patients in the fight against COVID-19.
A Nature study authored by a global team of scientists and led by Sumit Chanda, Ph.D., professor at Sanford Burnham Prebys Medical Discovery Institute, has identified 21 existing drugs that stop the replication of SARS-CoV-2, the virus that causes COVID-19.
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
Penn State Health Milton S. Hershey Medical Center has enrolled its first patients in the continuation of a clinical trial using the investigational antiviral drug remdesivir for treatment of COVID-19.
Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The University of Illinois at Chicago is enrolling patients in a second clinical trial to study the drug remdesivir as a treatment for COVID-19. Funded by the National Institute of Allergy and Infectious Disease (NIAID), this international randomized, placebo-controlled clinical trial will…
A Rutgers University expert who is leading a series of Remdesivir trials for people with COVID-19 is available to discuss the drug as a possible treatment as well as preliminary positive results from the trials. “As seen in a news…
Necessity being the mother of invention, Houston Methodist clinicians, researchers and staff have collaborated on a number of clinical device and research innovations in response to COVID-19. Houston Methodist Academic Institute leadership has continually emphasized translational research in new technologies.
Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health, is bringing clinical trials online at an unprecedented pace in response to COVID-19. A COVID-19 therapeutic task force of more than 20 multidisciplinary researchers positioned across the state of Texas has been putting their expertise in infectious disease, cardiology, immunology, molecular biology, and other specialties together to explore research opportunities for experimental prevention and treatment options and to develop investigator-initiated studies.
In a small group of patients hospitalized with severe complications of COVID-19 and treated with the experimental antiviral drug remdesivir, clinical improvement was observed in 68% of patients treated, according to an analysis co-authored by Jonathan Grein, MD, director of Hospital Epidemiology at Cedars-Sinai.
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.
Montefiore Health System and Albert Einstein College of Medicine has joined a clinical trial to evaluate the experimental drug remdesivir to treat people who are hospitalized with severe COVID-19 infection.
The University of Illinois at Chicago is participating in two clinical trials for COVID-19 treatments.
Cedars-Sinai has joined an international effort to test an experimental antiviral drug as a potential treatment for COVID-19 (coronavirus). The institution expects to enroll its first clinical trial participant this week.
UC Davis Health physicians and medical staff who treated the first case of community transmission of COVID-19 in the U.S. provide a detailed case study of her condition and the medical steps and challenges they experienced before arriving at a diagnosis and treatment.
The American Association for the Study of Liver Disease (AASLD) has released a clinical insight document for clinicians and frontline healthcare providers who are treating patients with liver disease during the COVID-19 pandemic. The document, which cites recent studies conducted in China, assesses how hepatologists and liver transplant physicians/surgeons and their patients may be affected by the COVID-19 virus (also known as SARS-CoV-2) and provides continued guidance on clinical approaches to disease management.
Physician-scientists at Beth Israel Deaconess Medical Center (BIDMC) are now enrolling patients in two clinical trials testing treatment options for COVID-19, the illness caused by the novel coronavirus. Two trials, led by infectious disease specialist Kathryn Stephenson, MD, MPH, will test the antiviral drug remdesivir for safety and efficacy against the respiratory infection that has sickened more than 300,000 and killed more than 15,000 around the world to date.
Researchers at four University of California Health medical centers have begun recruiting participants for a Phase II clinical trial to investigate the safety and efficacy of treating adult patients with COVID-19 with remdesivir, a drug that has shown promising activity against multiple viruses.
Francis Collins, M.D., Ph.D., director of the NIH, flew to Birmingham on Thursday, March 5, to start a long-anticipated visit to UAB. Collins soon learned he had a problem back home. Maryland public health officials were reporting the first two cases of COVID-19 in the county where the NIH sits.